Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer

International Journal of Colorectal Disease

Volumn 28, Issue 3, 2013, Pages 375-383

  Shim, Byoung Yong ^a   Jung, Ji Han ^a   Lee, Kang Moon ^a   Kim, Hyung Jin ^a   Hong, Sook Hee ^b   Kim, Sung Hwan ^a   Sun, Der Sheng ^a   Cho, Hyeon Min ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Anaerobic glycolysis; Glucose transporter 1; Hypoxia inducible factor 1 ; Lactate dehydrogenase5; Pyruvate dehydrogenase kinase1; Rectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE 5; PYRUVATE DEHYDROGENASE KINASE 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANAEROBIC GLYCOLYSIS; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE DISTRIBUTION; RECTUM BIOPSY; RECTUM CANCER; TREATMENT RESPONSE; UPREGULATION;

AGED; ANAEROBIOSIS; BIOPSY; CHEMORADIOTHERAPY; FEMALE; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LAPAROSCOPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN-SERINE-THREONINE KINASES; RECTAL NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879463466     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-012-1542-3     Document Type: Article

References (42)

1. Kockerling F, Reymond MA, Altendorf-Hofmann A, Dworak O, Hohenberger W (1998) Influence of surgery on metachronous distant metastases and survival in rectal cancer. J Clin Oncol 16(1):324-329 (Pubitemid 28041616)
2. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24(28):4620-4625. doi: 24/28/462010.1200/JCO.2006.06.7629 (Pubitemid 46630960)
3. Crane CH, Sargent DJ (2004) Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need? J Clin Oncol 22(15):2978-2981. doi: 10.1200/JCO.2004.04.953 JCO.2004.04.953 (Pubitemid 41103708)
4. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114-1123. doi: 355/11/111410.1056/NEJMoa060829 (Pubitemid 44394918)
5. Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, Coco C, Romano M, Mantello G, Palazzi S, Mattia FO, Friso ML, Genovesi D, Vidali C, Gambacorta MA, Buffoli A, Lupattelli M, Favretto MS, La Torre G (2008) Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72(1):99-107. doi: S0360-3016(07)04759-110.1016/j.ijrobp. 2007.12.019
6. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23(34):8688-8696. doi: JCO.2005.02.132910.1200/JCO.2005. 02.1329 (Pubitemid 46211512)
7. Kim BC (2011) Prognostic significance of tumor regression grade after preoperative chemoradiotherapy for rectal cancer. J Korean Soc Coloproctol 27(1):1-2. doi: 10.3393/jksc.2011.27.1.1
8. Suarez J, Vera R, Balen E, Gomez M, Arias F, Lera JM, Herrera J, Zazpe C (2008) Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis 10(6):563-568. doi: CDI142410.1111/j.1463-1318.2007.01424.x (Pubitemid 351803062)
9. Theodoropoulos G, Wise WE, Padmanabhan A, Kerner BA, Taylor CW, Aguilar PS, Khanduja KS (2002) T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 45(7):895-903 (Pubitemid 34761469)
10. Yeo SG, Kim DY, Kim TH, Chang HJ, Oh JH, Park W, Choi DH, Nam H, Kim JS, Cho MJ, Kim JH, Park JH, Kang MK, Koom WS, Nam TK, Chie EK, Lee KJ (2010) Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg 252(6):998-1004. doi: 10.1097/SLA.0b013e3181f3f1b100000658-201012000-00015
11. Warburg O (1956) On the origin of cancer cells. Science 123(3191):309-314
12. Semenza GL, Roth PH, Fang HM, Wang GL (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. The Journal of biological chemistry 269(38):23757-23763 (Pubitemid 24293585)
13. Semenza GL (2007) HIF-1 mediates the Warburg effect in clear cell renal carcinoma. Journal of bioenergetics and biomembranes 39(3):231-234. doi: 10.1007/s10863-007-9081-2 (Pubitemid 47619375)
14. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL (2006) Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway - a report of the Tumour Angiogenesis Research Group. J Clin Oncol 24(26):4301-4308. doi: 10.1200/JCO.2006.05.9501 (Pubitemid 46630788)
15. Wigfield SM, Winter SC, Giatromanolaki A, Taylor J, Koukourakis ML, Harris AL (2008) PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer 98(12):1975-1984. doi: 10.1038/sj.bjc.6604356 (Pubitemid 351821556)
16. Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202(3):654-662. doi: 10.1002/jcp. 20166 (Pubitemid 40175840)
17. Tredan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99(19):1441-1454. doi: djm13510.1093/jnci/djm135
18. Coleman CN (1996) Modulating the radiation response. Oncologist 1(4):227-231 (Pubitemid 126669382)
19. Janssen HL, Haustermans KM, Balm AJ, Begg AC (2005) Hypoxia in head and neck cancer: how much, how important? Head Neck 27(7):622-638. doi: 10.1002/hed.20223 (Pubitemid 40961072)
20. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR, Overgaard J (2001) Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 84(8):1070-1075. doi: 10.1054/bjoc.2001.1728S0007092001917288 (Pubitemid 32448504)
21. Nordsmark M, Loncaster J, Chou SC, Havsteen H, Lindegaard JC, Davidson SE, Varia M, West C, Hunter R, Overgaard J, Raleigh JA (2001) Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys 49(2):581-586. doi: S0360-3016(00)01493-0 (Pubitemid 32120259)
22. Nordsmark M, Overgaard J (2000) A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57(1):39-43
23. Hong SH, Roh SY, Ko YH, Won HS, Lee MA, Woo IS, Byun JH, Kang JH, Hong YS, Jung CK (2010) Prognostic significance of glycolytic metabolic change related to HIF-1α in oral squamous cell carcinomas. Korean J Pathol 44(4):360-369
24. Chung FY, Huang MY, Yeh CS, Chang HJ, Cheng TL, Yen LC, Wang JY, Lin SR (2009) GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer 9:241. doi: 1471-2407-9-24110.1186/1471-2407-9-241
25. Koukourakis MI, Giatromanolaki A, Simopoulos C, Polychronidis A, Sivridis E (2005) Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 22(1):25-30. doi: 10.1007/s10585-005-2343-7 (Pubitemid 41185858)
26. Brown JM (2000) Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 6(4):157-162. doi: S1357-4310(00)01677-4 (Pubitemid 30171366)
27. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56(19):4509-4515 (Pubitemid 26330463)
28. Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R (1999) Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 53(2):99-104
29. Yeung JM, Kalff V, Hicks RJ, Drummond E, Link E, Taouk Y, Michael M, Ngan S, Lynch AC, Heriot AG (2011) Metabolic response of rectal cancer assessed by 18-FDG PET following chemoradiotherapy is prognostic for patient outcome. Dis Colon Rectum 54(5):518-525. doi: 10.1007/DCR.0b013e31820b36f000003453-201105000- 00002
30. Martoni AA, Di Fabio F, Pinto C, Castellucci P, Pini S, Ceccarelli C, Cuicchi D, Iacopino B, Di Tullio P, Giaquinta S, Tardio L, Lombardi R, Fanti S, Cola B (2011) Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol 22(3):650-656. doi: mdq43310.1093/annonc/mdq433
31. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE (1998) Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 46(3):229-237. doi: S0167814097001862 (Pubitemid 28157272)
32. Jang NY, Kang SB, Kim DW, Kim JH, Lee KW, Kim IA, Kim JS (2011) The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer. Dis Colon Rectum 54(2):245-252. doi: 10.1007/DCR. 0b013e3181fcee6800003453-201102000-00020
33. Greijer AE, Delis-van Diemen PM, Fijneman RJ, Giles RH, Voest EE, van Hinsbergh VW, Meijer GA (2008) Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. Virchows Arch 452(5):535-544. doi: 10.1007/s00428-008-0578-9
34. Koukourakis MI, Giatromanolaki A, Polychronidis A, Simopoulos C, Gatter KC, Harris AL, Sivridis E (2006) Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer Sci 97(7):582-588. doi: CAS22010.1111/j.1349-7006.2006.00220.x (Pubitemid 44056605)
35. Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3(3):177-185. doi: S1550-4131(06)00062-310.1016/j.cmet.2006.02.002
36. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3(3):187-197. doi: S1550-4131(06)00060-X10.1016/j.cmet. 2006.01.012
37. Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D, Ichihara T, Kuroda Y, Maeda S, Kasuga M (2001) Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer 37(2):204-209. doi: S0959804900003713 (Pubitemid 32144697)
38. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G, Weiss A, Burstein DE (1998) GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83(1):34-40. doi:10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E (Pubitemid 28299626)
39. Chang HJ, Jung KH, Kim DY, Jeong SY, Choi HS, Kim YH, Sohn DK, Yoo BC, Lim SB, Kim DH, Ahn JB, Kim IJ, Kim JM, Yoon WH, Park JG (2005) Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol 36(4):364-371. doi: S004681770500046810.1016/j.humpath.2005.01.018 (Pubitemid 40591806)
40. Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, Malavasi N, Depenni R, Zironi S, Del Giovane C, Luppi G, Conte PF (2010) Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br J Cancer 103(7):1019-1024. doi: 660585310.1038/sj.bjc.6605853
41. Toiyama Y, Inoue Y, Saigusa S, Okugawa Y, Yokoe T, Tanaka K, Miki C, Kusunoki M (2010) Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. Clin Oncol (R Coll Radiol) 22(4):272-280. doi: S0936-6555(10)00002-610.1016/j.clon.2010.01.001
42. Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Fujikawa H, Matsushita K, Uchida K, Inoue Y, Kusunoki M (2012) Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surg Today 42(5):460-469. doi: 10.1007/s00595-011-0027-2